Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | $196K | $100M | — | — | — | — |
| Revenue growth | — | — | — | 50920.4% | — | — | — | — |
| Operating income | -$34.4M | -$24.4M | -$16.4M | -$15.6M | -$52.2M | -$12.9M | -$16.7M | -$11.1M |
| Operating margin | — | — | -8377.0% | -15.6% | — | — | — | — |
| Net income | -$39.4M | -$25.5M | -$19.7M | -$9.82M | -$42.4M | -$12.9M | -$9.57M | -$7.79M |
| Net margin | — | — | -10039.8% | -9.8% | — | — | — | — |
| EPS (diluted) | -$0.73 | -$0.30 | -$1.33 | -$0.27 | -$5.71 | -$1.35 | -$0.79 | -$0.47 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$23.0M | -$14.3M | -$17.2M | -$15.9M | -$12.3M | -$14.9M | -$8.87M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $16.9M | $14.2M | $50.9M | $30.3M | $27.9M | $23.0M | $22.1M | $17.0M |
| Total assets | $36.9M | $22.9M | $62.5M | $129M | $79.1M | $73.3M | $72.0M | $66.7M |
| Total liabilities | $25.9M | $9.86M | $6.80M | $20.4M | $11.2M | $11.6M | $5.38M | $2.76M |
| Shareholders' equity | $11.0M | $13.0M | $55.7M | $108M | $68.0M | $61.7M | $66.6M | $63.9M |
| Retained earnings | -$101M | -$126M | -$146M | -$156M | -$198M | -$211M | -$221M | -$228M |
| Shares (wtd avg diluted) | — | — | — | 36.8M | 7.44M | 9.53M | 12.1M | 16.5M |
Every figure is extracted from Grace Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.